The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Genentech, Inc.

Genentech, Inc.
NYSE: DNA
Change
symbol:
     
 NEWS FROM THE WIRES
Funds: Fund investors eye biotech
Aug 16 2001 09:33 AM PDT

Funds: Fund investors eye biotech
Aug 16 2001 09:33 AM PDT

Novartis contests FDA Zelnorm ruling, ends BMS pact
Aug 15 2001 10:59 PM PDT

Novartis contests FDA Zelnorm ruling, ends BMS pact
Aug 15 2001 10:59 PM PDT

Novartis contests FDA Zelnorm ruling, ends BMS pact
Aug 15 2001 10:59 PM PDT

More WIRE STORIES about this company

 NEWS FROM THE STANDARD
Power Surge
Jul 12 2001 09:02 AM PDT

FDA Catches Fed's Disease
Jul 11 2001 06:21 AM PDT

Corning Tests Investors' Optic Nerves
Jul 10 2001 10:06 AM PDT

Biotechies Swarm Into San Diego
Jun 26 2001 06:54 AM PDT

IPO Weekly: Checking in With the Hardy Few IPO Funds
Mar 30 2001 03:46 PM PST

 PROFILE
Designer genes are still chic at Genentech, one of the world's top biotech firms. More than 70% of sales come from nine products, including Rituxan (a non-Hodgkins lymphoma drug), Activase (post-heart attack treatment), Nutropin and Protropin (human growth hormones), and breast cancer treatment Herceptin. The company has an asthma product awaiting regulatory approval and other drugs in clinical development. Genentech earns royalties for hepatitis B vaccines, human and bovine growth hormones, and other products licensed to major drug companies. Genentech's foreign sales are handled by Hoffman-La Roche, whose parent Roche Holding also owns 58% of Genentech.

 COMPETITION
Centocor, Inc. (dossier)
Chiron Corporation (CHIR)
Novo Nordisk A/S (NVO)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 1,645.90
1-Yr. Sales Growth: 15.8%
Employees: 4,459
Revenue per employee: $369,118.64

 KEY PEOPLE
• Arthur D. Levinson
    CEO
• Louis J. Lavigne
    CFO

 CONTACT INFO
1 DNA Way
South San Francisco, CA 94080
US
Phone: 650-225-1000
Fax: 650-225-6000
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001